Atai Life Sciences Archives

Dave HodesJune 14, 2022

Editors Note: This story was originally published on June 13, but due to some technical problems we had to reset the website and as a result, the story got erased. This is the same story but republished. Biotechnology is always a dicey business to create, run, and make profitable. Psychedelics add a difficulty factor […]

Dave HodesMay 16, 2022

An earnings and business update video call today for Atai Life Sciences (NASDAQ-ATAI), a clinical-stage biopharmaceutical company that acquires, incubates and develops innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders, featured Atai Life Sciences CEO and Co-Founder Florian Brand; CSO and Co-Founder Srinivas Rao; and CFO Greg Weaver, as well as […]

Dave HodesApril 19, 2022

The year 2021 has not been kind to the psychedelics industry. The stock performances of the 60 publicly traded psychedelics companies on the Psychedelic Stock Index have been trending steadily downward since February 22, 2021, to their lowest point since the index began on June 1, 2020. The pandemic has definitely affected psychedelic business development. […]

Dave HodesMarch 9, 2022

When you take a big picture look at the psychedelics industry, you can easily get starry-eyed: Predictions of $6.85 billion industry by 2027. Mental health and wellness demands firing up a ready-made market. Support from more and more mainstream educational and institutional organizations creates credibility and access. Big money investors all in. Yet most of […]

Dave HodesMarch 7, 2022

On April 7, 2021, Atai Life Sciences , (NASDAQ: ATAI) a clinical-stage biopharmaceutical company developing psychedelics and non-psychedelic compounds for mental health wellness, acquired a majority stake in Delaware-based Psyber, a company working on a brain-to-computer (BCI) interface device. It is hoped that the Psyber brain-to-computer device, still in development, can enable various digital therapeutics […]

Debra BorchardtJune 18, 2021

Psychedelic industry leader Atai Life Sciences B.V. (Nasdaq: ATAI) announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of $15.00 per share. atai’s common shares are expected to begin trading on the Nasdaq Global Market on June 18, 2021 under the […]

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

In other news

The Daily Hit: January 4, 2024

Connecticut Attorney General Tells Unlicensed Cannabis Events Company to Stop

Testing Concerns Lead to Quarantine for 70% of Mississippi MMJ Goods

Tag: Atai Life Sciences

Are Psychedelics Still too Risky an Investment?

Atai Gives Business Update, Remains Well Funded

The Top Five Psychedelic Companies to Watch in 2022

Psychedelics Research Is No Guarantee For Success

Brain-to-Computer Devices Could Enter Everyday Life

Atai Life Sciences To Begin Trading Today

The Daily Hit - TEST TEST TEST

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

Get the latest cannabis news delivered right to your inbox